title: [Misleading advertisement on Opatanol].
abstract: In an advertisement in this journal, Alcon Nederland BV has recommended Opatanol (olopatadin) as the 'first choice medication/NHG practice guideline for Red eye/Allergic conjunctivitis'. However, the practice guideline of the Dutch College of General Practitioners (NHG) mentions the following 3 antihistaminica as first choice for the treatment of red eye/allergic conjunctivitis: azelastin, levocabastin or olopatadin. Therefore, it is concluded that the Alcon advertisement is misleading.
authors.affiliation: Nederlands Huisartsen Genootschap, Postbus 3231, 3502 GE Utrecht.
authors.forename: A E
authors.initials: AE
authors.lastname: Timmermans
mesh_terms: D000329:Advertising; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D009426:Netherlands; D000069605:Olopatadine Hydrochloride; D017410:Practice Guidelines as Topic
chemical_list: D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D006634:Histamine H1 Antagonists; D000069605:Olopatadine Hydrochloride